New blood tests, such as plasma p-tau217, are transforming Alzheimer's care by helping identify disease pathology earlier and closer to home. Meanwhile, disease-modifying therapies like lecanemab and donanemab target brain amyloid and have demonstrated slower cognitive decline in clinical trials. Two neurologists, Dr. Rany Aburashed and Dr. Cara Leahy, share their insights.
Forbes ·